< View All Healthcare Value Hub Articles
Ohio Survey Respondents Worry about High Drug Costs; Support a Range of Government Solutions
According to a survey of more than 1,600 Ohio adults, conducted from September 26 to October 14, 2024, respondents across the state are concerned about prescription drug costs and express a strong desire for policymakers to enact solutions.
Half (53%) of survey respondents reported being somewhat or very worried about affording the cost of prescription drugs. Worry varied substantially by income group, with respondents in households making less than $75,000 per year experiencing the most worry (see Figure 1).1 However, it is important to note that a large percentage of households making above $75,000 per year also reported worrying about the cost of prescription drugs.

In addition to the concerns about affording prescription drugs in the future, the survey reveals that more than a quarter of respondents (26%) have had to ration medication due to cost concerns in the last year, which for the purpose of this brief is defined as not filling a prescription, cutting pills in half or skipping a dose (see Figure 2).

Lower-income respondents and respondents enrolled in the Ohio Medicaid program, reported high rates of rationing medications due to cost. However, these hardships are also alarmingly prevalent in middle-income households. Also of note, respondents living in households with a person with a disability reported markedly higher rates of rationing medication due to cost when compared to respondents without a disabled household member (see Table 1).


Considering the challenges respondents reported concerning prescription drug affordability, as well as concerns about high health care costs generally,2 it is not surprising that Ohio respondents are generally dissatisfied with the health care system. In fact, just 35% of respondents agreed or strongly agreed that the United States health care system is “great,” while 73% agreed or strongly agreed that the United States health care system needs to change.
Ohio respondents also frequently reported that they believe that pricing decisions made by drug companies are a major reason for high health care costs. In fact, out of fifteen options, the most frequently cited reasons for high health care costs were:
- 76% — Drug companies charging too much money
- 71% — Insurance companies charging too much money
- 67% — Hospitals charging too much money
When it comes to tackling high drug costs, Ohio respondents endorsed a number of prescription drug-related strategies, including:
- 91% — Authorize the Attorney General to take legal action to prevent price gouging;
- 91% — Set standard prices for drugs to make them affordable;
- 90% — Cap out-of-pocket costs for life-saving medications, such as insulin;
- 89% — Prohibit drug companies from charging more in the U.S. than abroad; and
- 89% — Establish a Prescription Drug Affordability Board to examine evidence and establish acceptable costs for prescription drugs.
Moreover, there is strong bipartisan support for a variety of policies designed to address unaffordable prescription drug costs. For example, nearly all (92% of) respondents agreed that drug companies should be required to provide advance notice of price increases and to provide information to justify those increases, including 90% of respondents identifying as a Republican, 95% of respondents identifying as a Democrat and 90% of unaffiliated respondents (see Table 3).

While Ohio respondents overwhelmingly support government action to address high drug costs, they also see a role for themselves. Eighty percent (80%) would switch from a brand-name to an equivalent generic drug if given the chance, and 53% have sought or attempted to find the cost of a prescription drug beforehand.
CONCLUSION
The high burden of health care and prescription drug affordability, along with high levels of support for change, suggests that elected leaders and other stakeholders need to make addressing this consumer burden a top priority. Recent legislative action at both the federal and state levels may positively impact consumer affordability, specifically for prescription drugs used to treat chronic conditions such as insulin, epinephrine autoinjectors and asthma inhalers. Annual surveys can help assess whether progress is being made.
METHODOLOGY
Altarum’s Consumer Healthcare Experience State Survey (CHESS) is designed to elicit respondents’ views on a wide range of health system issues, including confidence using the health system, financial burden and possible policy solutions. This survey, conducted from September 26 to October 14, 2024, used a web panel from Dynata with a demographically balanced sample of approximately 1,700 respondents who live in Ohio. Information about Dynata’s recruitment and compensation methods can be found here. The survey was conducted in English or Spanish and restricted to adults ages 18 and older. Respondents who finished the survey in less than half the median time were excluded from the final sample, leaving 1,670 cases for analysis. After those exclusions, the demographic composition of respondents was as follows, although not all demographic information has complete response rates:

Percentages in the body of the brief are based on weighted values, while the data presented in the demographic table is unweighted. An explanation of weighted versus unweighted variables is available here. Altarum does not conduct statistical calculations on the significance of differences between groups in findings. Therefore, determinations that one group experienced a significantly different affordability burden than another should not be inferred. Rather, comparisons are for conversational purposes. The groups selected for this brief were selected by advocate partners in each state based on organizational/advocacy priorities. We do not report any estimates under N=100 and a co-efficient of variance more than 0.30.
Altarum in Action
Rhode Island Office of the Health Insurance Commissioner cites CHESS survey in letter to State House Committee on Health and Human Services about HB072 related to reimbursement rates and repealing affordability standards. Read more
Washington State Senator Patty Murray’s office cites the WA CHESS survey in press release about Senate Health, Education, Labor and Pensions (HELP) Committee hearing where Senator Murray questioned CEOs of major pharmaceutical companies about the high prices charged to Americans for their prescription drugs. Read more
Read More Altarum in Action Resources